Lynparza is used for the treatment and maintenance therapy of adult patients in the following conditions: 🔹 Ovarian Cancer: Maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (with or without BRCA mutations). 🔹 Breast Cancer: HER2-negative metastatic breast cancer with germline BRCA mutations. 🔹 Pancreatic Cancer: Maintenance treatment of metastatic pancreatic adenocarcinoma with BRCA mutations. 🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with mutations in DNA repair genes.

Dosage and administration

Sales Form: 1 pack contains 112 tablets of 150 mg (2 bottles/blisters of 56 tablets each).⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The standard dosage is 300 mg (two 150 mg tablets) twice daily. Total daily dose is 600 mg. Method: Tablets should be swallowed whole; do not chew, crush, or dissolve. They can be taken with or without food. Duration: Treatment continues until disease progression or unacceptable toxicity occurs. Important: Do not substitute Lynparza tablets with Lynparza capsules (50 mg) on a mg-to-mg basis without consulting a doctor, as they differ in bioavailability. Storage: Store in the original packaging at a temperature not exceeding 30°C.

⛔ Hypersensitivity: Hypersensitivity to olaparib or any components of the drug. ⛔ Pregnancy and Lactation: The drug has teratogenic effects. Strictly contraindicated for pregnant women. Breastfeeding must be discontinued during therapy and for one month after completion. ⛔ Severe Impairments: Severe renal impairment (dose adjustment is required for moderate cases). ⛔ Age: Not recommended for children and adolescents under 18 years of age.

The most common side effects observed with Lynparza: 🩸 Hematology: Anemia (low hemoglobin), neutropenia, leukopenia. Regular monitoring of complete blood count is required. 🤢 GI Tract: Nausea, vomiting, diarrhea, changes in taste (dysgeusia), decreased appetite. 🤕 General: Fatigue (asthenia), dizziness, headache. 🫁 Respiratory System: Shortness of breath, cough (rarely — pneumonitis). ⚠️ Important: If severe shortness of breath, fever, or signs of infection develop, contact your oncologist immediately. In rare cases, there is a risk of developing myelodysplastic syndrome (MDS).

Lynparza 150 — Olaparib 150 mg, 112 pcs, AstraZeneca

100% original product

Active ingredient

Olaparib

Manufacturer

AstraZeneca

Dosage 150 mg

Dosage form Tablets

Tablets per pack 112

Lynparza 150 — Olaparib 150 mg (112 Tablets)

Name: Lynparza 150
Brand: AstraZeneca
SKU: PROD-280
Price: 61779 UAH
Availability: InStock

61779₴ ~~66192₴~~ -7% On order · from 7 days

Lynparza (Olaparib) is an innovative antineoplastic drug, the first-in-class inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes. The medication is designed for targeted therapy of malignancies associated with DNA repair gene defects (such as BRCA1/2 mutations). Olaparib blocks the ability of cancer cells to repair their damaged DNA, leading to cell death while having minimal impact on healthy cells.

Manufacturer: AstraZeneca. Lynparza significantly increases progression-free survival and is considered the "gold standard" in maintenance therapy for ovarian cancer and certain forms of breast, pancreatic, and prostate cancer.

Key Features:

✅ Mechanism of "Synthetic Lethality": Selectively destroys tumor cells that have specific genetic defects.
✅ Wide Spectrum of Application: Effective in several types of solid tumors with BRCA mutations.
✅ Tablet Form: The modern 150 mg tablet form provides optimal bioavailability and administration convenience.

Lynparza is used for the treatment and maintenance therapy of adult patients in the following conditions:

🔹 Ovarian Cancer: Maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (with or without BRCA mutations).
🔹 Breast Cancer: HER2-negative metastatic breast cancer with germline BRCA mutations.
🔹 Pancreatic Cancer: Maintenance treatment of metastatic pancreatic adenocarcinoma with BRCA mutations.
🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with mutations in DNA repair genes.

Sales Form: 1 pack contains 112 tablets of 150 mg (2 bottles/blisters of 56 tablets each).

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The standard dosage is 300 mg (two 150 mg tablets) twice daily. Total daily dose is 600 mg.
Method: Tablets should be swallowed whole; do not chew, crush, or dissolve. They can be taken with or without food.
Duration: Treatment continues until disease progression or unacceptable toxicity occurs.
Important: Do not substitute Lynparza tablets with Lynparza capsules (50 mg) on a mg-to-mg basis without consulting a doctor, as they differ in bioavailability.
Storage: Store in the original packaging at a temperature not exceeding 30°C.

⛔ Hypersensitivity: Hypersensitivity to olaparib or any components of the drug.
⛔ Pregnancy and Lactation: The drug has teratogenic effects. Strictly contraindicated for pregnant women. Breastfeeding must be discontinued during therapy and for one month after completion.
⛔ Severe Impairments: Severe renal impairment (dose adjustment is required for moderate cases).
⛔ Age: Not recommended for children and adolescents under 18 years of age.

The most common side effects observed with Lynparza:

🩸 Hematology: Anemia (low hemoglobin), neutropenia, leukopenia. Regular monitoring of complete blood count is required.
🤢 GI Tract: Nausea, vomiting, diarrhea, changes in taste (dysgeusia), decreased appetite.
🤕 General: Fatigue (asthenia), dizziness, headache.
🫁 Respiratory System: Shortness of breath, cough (rarely — pneumonitis).
⚠️ Important: If severe shortness of breath, fever, or signs of infection develop, contact your oncologist immediately. In rare cases, there is a risk of developing myelodysplastic syndrome (MDS).